Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
(Thomson Reuters ONE) -
Targovax ASA (Targovax) will release its Q4 2015 results on Wednesday 1 March
2016 at 07:00 CET. The quarterly report and the presentation material will be
available at this time at www.targovax.com.
A presentation of the results will be held at 09:30 CET at Hotel Continental
Conference Center, Stortingsgaten 24/26, Oslo, Norway.
CEO Gunnar Gårdemyr, CFO Øystein Soug and CMO Magnus Jäderberg will be
representing the company.
At 14:00 CET (08:00 EST) the same day, Targovax will host a telephone
conference, including a presentation of the results, following with a Q&A
session. Call in details below.
Please make sure to dial in at least 5-10 minutes ahead of time to complete your
registration.
Participant information:
Call in numbers:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
See attached list for more dial in numbers.
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
Access code:
16490430#
For further information, please contact:
Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr(at)targovax.com
Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
Elisabeth Haugen Barter
PR Coordinator
Phone: +47 900 61 664
Email: elisabeth.barter(at)targovax.com
About Targovax: "Arming patient''s immune system to fight cancer"
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aim to become a leader in its area. The
company is currently developing two complementary and highly targeted approaches
in immuno-oncology:
Oncos 102 is a virus-based immunotherapy platform based on engineered oncolytic
viruses armed with potent immune-stimulating transgenes targeting solid tumors.
This treatment may reinstate the immune system''s capacity to recognize and
attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax works towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
The product candidates will be developed in combination with multiple treatments
in several cancer indications, including checkpoint inhibitors. Targovax also
has a number of other cancer immune therapy candidates in the early stage of
development. For more information go to www.targovax.com.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#1988632]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2016 - 02:00 Uhr
Sprache: Deutsch
News-ID 1417635
Anzahl Zeichen: 2438
contact information:
Contact person:
Town:
Lysaker
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 126 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
